Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block

Pembrolizumab is a monoclonal antibody directed towards programmed cell death protein 1 (PD-1) and is an antineoplastic drug which has a growing variety of oncologic uses. Pembrolizumab is commonly associated with immune-related adverse events (IRAEs) but is infrequently noted to cause cardiotoxicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Alisha, Riaz, Sana, Carhart, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007942/
https://www.ncbi.nlm.nih.gov/pubmed/32047674
http://dx.doi.org/10.1155/2020/8428210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007942/
https://www.ncbi.nlm.nih.gov/pubmed/32047674
http://dx.doi.org/10.1155/2020/8428210

Ejemplares similares